Gilead has handed back a next-gen hepatitis B (HBV) antiviral to Assembly Biosciences, while the two companies continue to partner on other assets. It means Assembly is now back in sole control of ABI ...

Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...

The UK Health Security Agency (UKHSA) said that as of 5pm on Wednesday, 15 cases of meningitis have been confirmed and a further 12 are under investigation ...

Meningitis, particularly bacterial meningitis, can be deadly if left untreated: according to the World Health Organization, around one in six people affected by this type of meningitis die, and ...

The symptoms can be easily dismissed but can also leave you critically ill in hours ...

A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.

Researchers at the George Washington University School of Medicine and Health Sciences in partnership with Baylor College of Medicine report encouraging results from a phase 2 clinical trial ...

Lawyers for both sides in the federal lawsuit, brought by six medical organizations, are trying to understand the ramifications of the judge’s decision.

The Centers for Disease Control and Prevention released a report March 12 on the effectiveness of the flu vaccine for the ...

"Falling vaccination rates, inadequate health policy, and a lack of preparedness can trigger a crisis that brings an entire nation to its knees," writes the Governor of Hawaii.

The FDA has approved a third respiratory syncytial virus vaccine for high-risk adults aged younger than 50 years — a ...

Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the Arexvy vaccine.